FIG. 3.

Relationship between isradipine treatment and total and part 3 UPDRS scores. (A) Total UPDRS scores at the end of the STEADY-PD II trial for placebo (n = 25), 5 mg/day isradipine (n = 22) and 10 mg/day isradipine (n = 25) treatment groups. There was no adjustment for symptomatic therapy. Placebo and 10 mg/day isradipine groups were significantly different (P = 0.04). Data are shown as means/SEMs. (B) The difference in total UPDRS scores between placebo and 10 mg/day isradipine treatment groups remained after adjustment for total daily dose of symptomatic medication (P = 0.08); the adjustment was based on placebo group data in the STEADY-PD III trial and the methodology used previously⁶; see Methods for details. (C) Part 3 UPDRS scores at the end of the STEADY-PD II trial for placebo (n = 25), 5 mg/day isradipine (n = 22) and 10 mg/day isradipine (n = 25) treatment groups. There was no adjustment for symptomatic therapy. Placebo and 10 mg/day isradipine groups were significantly different (P = 0.04). Data are shown as means/SEMs. (D) The difference in part 3 UPDRS scores between placebo and 10 mg/day isradipine treatment groups remained after adjustment for total daily dose of symptomatic medication but was not statistically significant (P = 0.1); the adjustment was based on part 3 UPDRS placebo group data in the STEADY-PD III trial and the methodology used previously⁶; see Methods for details. (E) Total unadjusted UPDRS scores for patients not taking rasagiline or selegiline in the placebo (n = 15), 5 mg/day isradipine (n = 12) and 10 mg/day isradipine (n = 14) treatment groups. Placebo and 10 mg/day isradipine groups were significantly different (P = 0.01). (F) Adjustment for total daily dose of symptomatic medication did not change the pattern of the results. Placebo and 10 mg/day isradipine groups were significantly different (P = 0.05).